LOS ANGELES - Immix Biopharma, Inc. (NASDAQ:IMMX) closed an underwritten offering of 16,778,524 shares at $8.94 each.
Net proceeds were approximately $140.65 million after deductions. The capital strengthens Immix's balance sheet.
Stock trades at $8.78 with a market cap of $459.61 million. Analysts maintain price targets between $14.80 and $22.78.
Morgan Stanley led as book-running manager, with BofA Securities as book-runner. LifeSci Capital, Mizuho and Needham & Company served as co-lead managers.
The offering was made under a shelf registration statement filed with the SEC.
Immix Biopharma develops treatments for AL Amyloidosis. Its lead candidate is NXC-201, a BCMA-targeted CAR T therapy.
In other recent news, the company priced a $150 million stock offering and reported a 95% complete response rate in its NEXICART-2 trial.
